Alnylam Pharmaceuticals, Inc.
ALNY
$438.93
$3.830.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -66.28M | -57.48M | -83.76M | -111.57M | -16.89M |
| Total Depreciation and Amortization | 13.94M | 14.41M | -20.55M | 27.04M | 15.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 155.99M | 141.81M | 83.86M | 97.51M | 164.40M |
| Change in Net Operating Assets | 50.08M | -217.05M | -74.21M | 30.73M | -38.35M |
| Cash from Operations | 153.73M | -118.31M | -94.66M | 43.71M | 124.16M |
| Capital Expenditure | -14.29M | -8.97M | -9.09M | -4.19M | -8.02M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -127.09M | 122.74M | -43.82M | -26.06M | 41.96M |
| Cash from Investing | -141.38M | 113.77M | -52.91M | -30.25M | 33.94M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 81.22M | 49.37M | 36.28M | 108.04M | 132.78M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -27.47M | -5.28M | -5.28M | -5.28M | -1.28M |
| Cash from Financing | 53.76M | 44.08M | 31.00M | 102.76M | 131.50M |
| Foreign Exchange rate Adjustments | 27.51M | 14.06M | -17.27M | 15.09M | -3.12M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 93.61M | 53.60M | -133.85M | 131.31M | 286.47M |